Financial reports
10-K
2023 FY
Annual report
21 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
2 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
31 Mar 22
Current reports
8-K
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
21 Mar 24
8-K
Results of Operations and Financial Condition
7 Mar 24
8-K
ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates
9 Nov 23
8-K
Regulation FD Disclosure
25 Sep 23
8-K
Other Events
20 Sep 23
8-K
ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates
10 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
28 Jun 23
8-K
Regulation FD Disclosure
16 May 23
8-K
ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results
15 May 23
8-K
Regulation FD Disclosure
9 May 23
Registration and prospectus
S-8
Registration of securities for employees
21 Mar 24
S-3
Shelf registration
20 Apr 23
S-8
Registration of securities for employees
17 Jan 23
S-8
Registration of securities for employees
3 Jan 22
S-3
Shelf registration
3 Jan 22
S-8
Registration of securities for employees
29 Mar 21
S-8
Registration of securities for employees
4 Dec 20
424B4
Prospectus supplement with pricing info
4 Dec 20
S-1MEF
Registration of additional securities for an S-1
3 Dec 20
S-1/A
IPO registration (amended)
3 Dec 20
Proxies
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
DEFA14A
Additional proxy soliciting materials
2 Nov 22
DEFA14A
Additional proxy soliciting materials
27 Oct 22
DEFA14A
Additional proxy soliciting materials
27 Oct 22
DEFA14A
Additional proxy soliciting materials
21 Oct 22
DEFM14A
Proxy related to merger
6 Oct 22
PRER14A
Preliminary revised proxy
16 Sep 22
PREM14A
Preliminary proxy related to merger
11 Aug 22
DEFA14A
Additional proxy soliciting materials
21 Jul 22
Other
EFFECT
Notice of effectiveness
4 May 23
CORRESP
Correspondence with SEC
1 May 23
UPLOAD
Letter from SEC
24 Apr 23
UPLOAD
Letter from SEC
7 Oct 22
CORRESP
Correspondence with SEC
16 Sep 22
UPLOAD
Letter from SEC
9 Sep 22
EFFECT
Notice of effectiveness
14 Jan 22
CORRESP
Correspondence with SEC
11 Jan 22
UPLOAD
Letter from SEC
10 Jan 22
EFFECT
Notice of effectiveness
4 Dec 20
Ownership
4
Sarina Tanimoto
24 Apr 24
4
Richard E Lowenthal
24 Apr 24
4
Sarina Tanimoto
22 Apr 24
4
Richard E Lowenthal
22 Apr 24
4
Sarina Tanimoto
17 Apr 24
4
Richard E Lowenthal
17 Apr 24
4
Sarina Tanimoto
10 Apr 24
4
Richard E Lowenthal
10 Apr 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
29 Mar 24
4
Rajeev M. Shah
27 Mar 24